Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 August 2021, including: AstraZeneca PLC looks to return to normality; Bayer AG’s hopes for Kerendia; Novartis AG’s plans for a new version of Zolgensma; Arcturus Therapeutics Ltd. benefits from mRNA interest; and AbbVie Inc. changes tack in Alzheimer’s.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Bayer Backs Kerendia To Be A Blockbuster" - Scrip, 5 Aug, 2021.)

(Also see "Novartis Can Again Pursue Bigger Zolgensma Market After FDA Lifts OAV-101 Hold" - Scrip, 3 Aug, 2021.)

(Also see "Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA" - Scrip, 4 Aug, 2021.)

(Also see "AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid" - Scrip, 30 Jul, 2021.)

 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel